High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody
- 31 July 2011
- journal article
- research article
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 122 (1), 171-177
- https://doi.org/10.1016/j.ygyno.2011.03.002
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-trop-2 monoclonal antibodyCancer, 2011
- Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patientsEuropean Journal of Cancer, 2010
- Trop2: A possible therapeutic target for late stage epithelial carcinomasBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2009
- Overexpression of Epithelial Cell Adhesion Molecule in Primary, Metastatic, and Recurrent/Chemotherapy-Resistant Epithelial Ovarian CancerInternational Journal of Gynecologic Cancer, 2009
- Management of Recurrent Ovarian Carcinoma: Current Status and Future DirectionsSeminars in Oncology, 2009
- Ovarian CancerAnnual review of pathology, 2009
- High expression of TROP2 correlates with poor prognosis in pancreatic cancerBritish Journal of Cancer, 2008
- Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancersMolecular Cancer Therapeutics, 2008
- TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavityLaboratory Investigation, 2008
- Specificity and properties of MAb RS7‐3G11 and the antigen defined by this pancarcinoma monoclonal antibodyInternational Journal of Cancer, 1993